Bridging the Continuous Glucose Monitoring decision gap: from glycaemic variability data to actionable stability in diabetes care

1

The 2026 proposal introduces a three-stage model for type 2 diabetes based on β-cell function decline and continuous glucose monitoring metrics.
2

Barriers to effective diabetes management include metric overload, clinical inertia prioritizing hypoglycaemia avoidance, and lack of structured frameworks for CGM insights.
3

A pragmatic three-step closed-loop clinical model is proposed to address these barriers, focusing on sustainable glycaemic stability and stage-specific therapeutic responses.
4

The model emphasizes time in tight range (TITR) as a critical metric for assessing glycaemic stability, with specific thresholds for each disease stage.
5

Bridging the CGM decision gap requires prospective validation of targets and integration of decision-support tools into electronic health records.

1